Check for updates

OPEN ACCESS

EDITED BY Yan Chen, Sichuan Cancer Hospital, China

REVIEWED BY Bei Xu, Sichuan University, China Qiuju Wang, Sichuan Cancer Hospital, China

*Correspondence Ning Shi, ⊠ 644607165@qq.com

¹These authors have contributed equally to this work

RECEIVED 21 January 2025 ACCEPTED 26 February 2025 PUBLISHED 18 March 2025

CITATION

Geng S, Shen Y, Zhang C, Wang N, Gao X, Luo X and Shi N (2025) Correlation between UGT1A1 polymorphism and efficacy and toxicity of irinotecan in Chinese cancer patients. *Front. Pharmacol.* 16:1563566. doi: 10.3389/fphar.2025.1563566

COPYRIGHT

© 2025 Geng, Shen, Zhang, Wang, Gao, Luo and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correlation between UGT1A1 polymorphism and efficacy and toxicity of irinotecan in Chinese cancer patients

Shuai Geng^{1†}, Yulong Shen^{2†}, Chen Zhang^{3†}, Nan Wang⁴, Xinyue Gao⁴, Xinyu Luo⁴ and Ning Shi¹*

¹Department of Pharmacy, The Ninth Medical Center, Chinese PLA General Hospital, Beijing, China, ²Department of Radiotherapy, The Ninth Medical Center, Chinese PLA General Hospital, Beijing, China, ³Department of Medical Imaging, The Ninth Medical Center, Chinese PLA General Hospital, Beijing, China, ⁴Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

Objective: To assess the association between UGT1A1*6/*28 polymorphisms and Irinotecan (IRI) efficacy/toxicity in Chinese cancer patients.

Method: We systematically searched PubMed, Cochrane, CNKI, and Wanfang databases. Two investigators independently conducted literature screening, data extraction, and meta-analysis using Revman 5.4.

Results: This study included 19 clinical trials or case-control studies, with a total of 1,698 patients. Meta-analysis showed that, ① There was no correlation between UGT1A1*6 or UGT1A1*28 gene polymorphism and IRI efficacy; ② UGT1A1*6 or UGT1A1*28 gene polymorphisms are associated with grade 3–4 diarrhea, grade 3–4 neutropenia, and grade 3–4 leukopenia, and the above-mentioned toxic reactions are more common in wild types (GG and TA6/6). ③ There was no correlation between UGT1A1*6 and UGT1A1*28 mutations and the efficacy of IRI; ④ The double wild type was more prone to grade 0–2 neutropenia, the single-site variant was more prone to grade 3–4 neutropenia, the single-site variant was more prone to grade 3–4 neutropenia, the single-site variant was more prone to grade 3–4 neutropenia, the single-site variant was more prone to grade 3–4 neutropenia, but none of them were related to leukopenia.

Conclusion: UGT1A1*6/*28 polymorphisms predict IRI-induced toxicity severity but not therapeutic efficacy in Chinese patients. These variants may serve as predictive biomarkers for personalized IRI chemotherapy.

KEYWORDS

gene polymorphism, UGT1A1*6, UGT1A1*28, irinotecan, efficacy, toxicity, systematic review

Introduction

Irinotecan (IRI), a semi-synthetic water-soluble camptothecin derivative, exerts its antitumor activity through its active metabolite SN-38 (7-ethyl-10-hydroxycamptothecin), a potent DNA topoisomerase I inhibitor. By stabilizing the DNA-topoisomerase I complex during replication, SN-38 induces persistent DNA single-strand breaks, thereby blocking DNA replication and suppressing RNA synthesis, ultimately leading to tumor cell death (De et al., 2018). As a first-line chemotherapeutic agent, IRI is extensively used in treating advanced solid malignancies, including colorectal cancer, gastric cancer, and small cell lung

cancer, particularly demonstrating survival benefits in gastrointestinal tumors. However, its clinical utility is significantly hampered by dose-limiting toxicities: delayed-onset diarrhea (46% incidence) and neutropenia (30% incidence), both associated with life-threatening complications and treatment discontinuation rates exceeding 50% in severe cases (Paulík et al., 2020).

The metabolic detoxification of IRI is primarily mediated by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), which catalyzes the glucuronidation of SN-38 to its inactive form SN-38G. Genetic polymorphisms in UGT1A1 profoundly influence this metabolic pathway, with two key variants-UGT1A128 (characterized by a TA-repeat polymorphism in the promoter region) and UGT1A16 (a missense mutation in exon 1)showing ethnic-specific distributions and functional impacts. These polymorphisms reduce UGT1A1 enzymatic activity by 30%-70%, leading to SN-38 accumulation and elevated toxicity risks. Notably, UGT1A128 is more prevalent in Caucasian populations (30%-40%), whereas UGT1A16 predominates in Asian cohorts (15%-20%) (Nelson et al., 2021; Takano and Sugiyama, 2017; Dean, 2018; Deng, 2021). While substantial evidence supports the role of UGT1A1 variants in predicting IRIinduced hematologic and gastrointestinal toxicity, their association with therapeutic efficacy remains controversial. Some studies suggest genotype-dependent differences in tumor response rates, whereas others, including a pivotal analysis by (Matsuoka and Ando, 2015). found no significant correlation between UGT1A1 polymorphisms and clinical outcomes. This discrepancy underscores the need for population-specific investigations to clarify the dual predictive potential of these genetic markers.

To address this knowledge gap in Chinese patients, we conducted a systematic meta-analysis evaluating the impact of UGT1A16 and UGT1A128 polymorphisms on both toxicity profiles and treatment efficacy of IRI-based regimens. Our findings aim to optimize genotype-guided dosing strategies and advance precision oncology practices in China.

Materials and methods

Search strategy and study selection

To comprehensively and thoroughly investigate the impact of UGT1A16 and UGT1A128 gene polymorphisms on the efficacy and adverse reactions of irinotecan (Irinotecan, IRI) in cancer treatment, we employed a comprehensive literature search strategy. Firstly, leveraging advanced computer technology, we systematically searched multiple authoritative Chinese and English databases, including PubMed, Cochrane Library, CNKI (China National Knowledge Infrastructure), and Wanfang Data. During the search process, we combined the use of subject headings and free-text terms to ensure the comprehensiveness and accuracy of the search results. Subject headings allowed for precise targeting of research in the relevant fields, while free-text terms captured a broader range of literature potentially related to the topic, enhancing search efficiency when used together.

In terms of Chinese search terms, we meticulously selected vocabulary closely related to the topic, including irinotecan, gene polymorphism, uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), tumor, colon cancer, rectal cancer, gastric cancer, small cell lung cancer (SCLC), clinical trial, and randomized controlled trial. These terms comprehensively covered our research interests, ensuring the completeness of the search results.

For English search terms, we adopted corresponding English vocabulary matching the Chinese terms, including Irinotecan, IRI, gene polymorphism, UGT1A16, UGT1A128, colon cancer, rectal cancer, gastric cancer, SCLC, clinical trial, and randomized controlled trial. The use of these English terms enabled us to access the latest research findings on this topic internationally.

The search time frame covered from the inception of each database to December 2023, ensuring that we captured all potential relevant studies. Furthermore, to further improve the recall rate of the search, we manually reviewed the references cited within the literature. This approach allowed us to discover important literature that might have been overlooked by database search strategies, thereby enriching our research materials.

By combining multiple strategies, we ensured a comprehensive and in-depth exploration of the impact of UGT1A16 and UGT1A128 gene polymorphisms on the efficacy and adverse reactions of irinotecan in cancer treatment. These efforts will provide us with more accurate and comprehensive research evidence, contributing to the advancement of research in this field.

We specify exclusion and inclusion criteria in advance. Inclusion criteria: (1) Study type: clinical trial or randomized controlled trial based on UGT1A1 gene polymorphism and IRI efficacy and adverse reactions; (2) Study population: Chinese population; (3) Subjects: Patients diagnosed as cancer by pathology or cytology; (4) UGT1A1 gene polymorphism: UGT1A1*6 and UGT1A1*28; (5) Outcome indicators: The disease remission rate (RR = CR + PR) and toxic reactions (diarrhea, neutropenia, leukopenia, thrombocytopenia and hemoglobinemia) were analyzed in recessive gene model (i.e., wild type VS mutant). Exclusion criteria (1) Review, meta-analysis, animal experiments, case reports, summaries, editorials and letters to editors. (2) Repeated published literature; (3) Non-Chinese and English literature; (4) There is no reference data; (5) Single cohort non-comparative study.

Data extraction and quality assessment

The two evaluators independently utilized literature management tools to conduct double-blind screening, ensuring that neither evaluator could view the other's results until all screenings were completed independently. A structured screening form was designed, mandating the completion of inclusion/ exclusion rationales item by item to minimize subjective judgment bias. Additionally, consistency was reported separately for the title/abstract screening and full-text screening phases to demonstrate rigor. In cases of disagreement, the two evaluators

Abbreviations: CR, Complete response; DV, Double variant; DW, Double wild type; FDA, Food and Drug Administration; IRI, Irinotecan; OR, Odds ratio; PR, Partial response; PD, Progressive disease; RR, Relative risk; SN-38G, Glycosylated SN-38; SNP, Single nucleotide polymorphism; SD, Stable disease; SV, Single variant; UGT1A1, Uridine diphosphate glucuronide transferase 1A1; NOS, Newcastle-Ottawa scale.

conducted a second independent review of the disputed articles, with a focus on verifying whether the original screening criteria aligned with the predefined standards. If disagreements persisted, a consensus meeting was convened to discuss each item individually and invoke the terms of the research protocol to reach an agreement. Alternatively, a third senior researcher (typically the project leader or methodological expert) was introduced to conduct an independent assessment, with their decision serving as the final outcome. The contents of data extraction mainly include: (1) The first author/ published year; (2) Basic characteristics of the subjects: age, sex, etc.,; (3) Sample size; (4) The method of genotyping, UGT1A1*6 and UGT1A1*28 polymorphism; (5) Curative effect and toxicity outcome index. For the original study with multiple groups, the data related to this study are extracted.

The Newcastle-Ottawa scale (NOS) was used to evaluate the quality of the literature (Lazarus et al., 2019), and the quality of the included studies was evaluated according to the following eight criteria: (1) Representativeness of the exposure cohort; (2) Selection of non-exposed queues; (3) Determination of exposure method; (4) No outcome events occurred before the study began; (5) Comparability between exposed queues and non-exposed queues; (6) Evaluation of outcome events; (7) Whether the follow-up time is long enough; (8) Whether the follow-up is complete. Documents rated 7-9 are considered "high" in quality, 4–6 as "average" and 3 or less as "low". The quality evaluation is carried out independently by two researchers and cross-checked. If there is any difference, please ask the third researcher to help solve it.

Statistical analysis

RevMan5.4 software was used for Meta-analysis. The correlation between UGT1A1*6 and UGT1A1*28 gene polymorphism and the efficacy and adverse reactions of IRI was evaluated by odds ratio (OR), relative risk (RR) and 95% CI. Heterogeneity included in the study results was analyzed by χ^2 test (the test level was $\alpha = 0.1$), and the size of heterogeneity was quantitatively judged by combining I². When P > 0.1 and I² < 50%, it indicates that there is no statistical heterogeneity in each RCTs, and a fixed-effect model is used; On the contrary, the random effects model was used under the premise of excluding clinical heterogeneity. Significant clinical heterogeneity was treated by subgroup analysis or sensitivity analysis, or only descriptive analysis. According to the recommendation of Cochrane Systematic Review Production Manual, when the number of included literatures is ≥ 10 , the publication bias test is carried out by funnel diagram.

Results

Basic characteristics and quality evaluation of literature

1,197 related literatures were initially detected, including PubMed (n = 610), Embase (n = 344), The CochraneLibrary (n = 132), CNKI (n = 91) and Wanfang Database (n = 20). 533 duplicate literatures were eliminated by EndNote software, and 645 were excluded after reading. Finally, 19 literatures were included (Yin and Gao, 2014; Chen et al., 2018; Chen et al., 2017a; Pan et al., 2017; Wu et al., 2013; Zhang et al., 2012; Yang et al., 2017; Ji et al., 2010; Zhang et al., 2014; Jia and Fu, 2019; Zhang et al., 2019; Lv et al., 2012; Wang et al., 2018; Yan et al., 2012; Hou et al., 2023; Hua et al., 2019; Bai et al., 2017; Li et al., 2014; Xu et al., 2016) and 1,698 cancer patients were included. The retrieval process, the basic characteristics of the research and the results of bias risk assessment are shown in Figure 1 and Table 1.

Meta-analysis results

Correlation of UGT1A1*6 polymorphism with efficacy and toxicity of IRI

Efficacy evaluation

According to the evaluation standard of curative effect of solid tumor (RECIST 1.1), it can be divided into complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). We selected disease remission rate (RR = CR + PR) to evaluate the relationship between UGT1A1*6 gene polymorphism and the efficacy of IRI. A total of 11 studies and 912 cancer patients were included. We used a recessive gene model (GG vs. GA + AA) to analyze the included studies. Heterogeneity analysis showed that I² = 36%, P = 0.11, and there was no statistical heterogeneity among the studies. Fixed effect model was used for analysis. The results showed that there was no significant difference in disease remission rate [OR = 1.00, 95% CI (0.72, 1.40), P = 1.00] between wild type (GG) and mutant type (GA + AA) in recessive gene model (P > 0.05), as shown in Figure 2. It was suggested that there is no correlation between UGT1A1*6 gene polymorphism and IRI curative effect.

Toxicity

Diarrhea (1) Grade 0-2: Recessive gene model (GG vs. GA + AA) was included in 14 studies. Heterogeneity analysis showed that $I^2 = 75\%$, P < 0.00001, and there was statistical heterogeneity among the studies. The results showed that the incidence of grade 0-2 diarrhea (RR = 1.19, 95% CI (0.92, 1.54), P = 0.18) was not significantly different between wild type (GG) and mutant type (GA + AA) of UGT1A1*6 (P > 0.05); (2) Grade 3-4: Recessive gene model (GG vs. GA + AA) was included in 17 studies. Heterogeneity analysis showed that $I^2 = 25\%$, P = 0.16, and there was no statistical heterogeneity among the studies. The results showed that the incidence of 3-4 diarrhea in UGT1A1*6 wild type (GG) was lower than that in mutant type (GA + AA) during IRI chemotherapy, and the difference was statistically significant [RR = 0.38, 95% CI (0.29, 0.48), P < 0.00001], as shown in Figure 3. Therefore, UGT1A1*6 gene polymorphism is correlated with the incidence of grade 3-4 diarrhea in cancer patients during IRI chemotherapy, and the incidence of wild type (GG) is lower.

Neutropenia (1) Grade 0–2: The recessive gene model (GG vs. GA + AA) was included in 13 studies. Heterogeneity analysis showed that $I^2 = 54\%$, P = 0.01, and there was statistical heterogeneity among the studies. The results showed that the incidence of grade 0–2 neutropenia in UGT1A1*6 wild type (GG) was higher than that in mutant type (GA + AA) during



IRI chemotherapy, and the difference was statistically significant [RR = 1.40, 95% CI (1.10, 1.79), P = 0.006]; (2) Grade 3–4: The recessive gene model (GG vs. GA + AA) was included in 17 studies, and the heterogeneity analysis showed that its I² = 51%, P = 0.007, and there was statistical heterogeneity among the studies. The results showed that the incidence of 3-4 neutropenia in cancer treated with IRI was lower in wild type GG than in mutant type (GA + AA), and the difference was statistically significant [RR = 0.50, 95% CI (0.37, 0.68), P < 0.00001], as shown in Figure 4. Therefore, UGT1A1*6 gene polymorphism is correlated with the incidence of neutropenia in cancer patients during IRI chemotherapy, and the incidence of mild neutropenia is higher in wild type (GA + AA).

Leukopenia (1) Grade 0–2: Recessive gene model (GG vs. GA + AA) was included in eight studies. Heterogeneity analysis showed that

 $I^2 = 57\%$, P = 0.02, and there was statistical heterogeneity among the studies. The results showed that there was no significant difference in the incidence of grade 0–2 leukopenia between wild type (GG) and mutant type (GA + AA) of UGT1A1*6 during IRI chemotherapy [RR = 1.13, 95% CI (0.88, 1.44), P = 0.35]; (2) Grade 3–4: Recessive gene model (GG vs. GA + AA) was included in nine studies. Heterogeneity analysis showed that $I^2 = 40\%$, P = 0.10, and there was no statistical heterogeneity among the studies. The results showed that the incidence of grade 3–4 leukopenia in UGT1A1*6 wild type (GG) was lower than that in mutant type (GA + AA) during IRI chemotherapy for cancer, and the difference was statistically significant [RR = 0.53, 95% CI (0.33, 0.86), P = 0.009], as shown in Figure 5. Therefore, UGT1A1*6 gene polymorphism is correlated with the incidence of grade 3–4 leukopenia in cancer patients during IRI chemotherapy, and the incidence of wild type (GG) is lower.

Involved studies	Year	Region	Cancer types	Number	Gender (Male/ Female)	Age	Sample	NOS
Yin H [9]	2014	Suzhou	Gastrointestinal tumor	68	46/22	34-78	Peripheral blood	7
Chen SJ [10]	2018	Guangxi	Metastatic colorectal cancer	86	54/32	21-78	Peripheral blood	7
Chen R [11]	2017	Xinjiang	Advanced colorectal cancer	62	38/24	33-63	Peripheral blood	7
Pan RY [12]	2017	Jiangsu	Advanced colorectal cancer	60	37/23		Peripheral blood	7
Wu Q [13]	2013	Anhui	Metastatic colorectal cancer	38	27/11	25-77	Peripheral blood	7
Zhagn XJ [14]	2012	Guangzhou	Metastatic colorectal cancer	56	35/21	21-78	Peripheral blood	7
Yang MD [15]	2016	Liaoning	Colorectal cancer	65			Peripheral blood	7
Ji CS [16]	2010	Anhui	Advanced colorectal cancer	64	42/22		Peripheral blood	7
Zhang Y [17]	2014	Beijing	Advanced colorectal cancer	102	67/35	24-74	Peripheral blood	7
Jia XY [18]	2019	Wuhan	Colorectal cancer	110		18-75	Peripheral blood	7
Zhang CL [19]	2019	Shanghai	Metastatic colorectal cancer	38	25/13	45-79	Peripheral blood	7
Lu YL [20]	2012	Hebei	Gastrointestinal tumor	57	34/23	21-74	Peripheral blood	7
Wang Q [21]	2018	chekiang	Colorectal cancer	72	38/34	24-75	Peripheral blood	7
Wang Y [22]	2012	Beijing	Advanced colorectal cancer	192	114/78	26-81	Peripheral blood	7
Hou WJ [23]	2023	Nanjing	Small cell lung cancer	77	64/13	53-63	Peripheral blood	7
Hua L [24]	2019	Guangxi	Small cell lung cancer	120	72/48	19–72	Peripheral blood	7
Yu Bai [25]	2017	Beijing	Lung cancer, esophageal cancer, colon cancer	81	67/14	28-79	Peripheral blood	7
Minmin Li [26]	2014	Shandong	Metastatic colorectal cancer	167	87/80	27-71	Peripheral blood	7
Chunlei Xu [27]	2016	Xinjiang	Advanced colorectal cancer	183	124/59		Peripheral blood	7

TABLE 1 Characteristics and methodological quality of involved studies [9-27].

Thrombocytopenia (1) Grade 0–2: A total of six studies were included in the recessive gene model (GG vs. GA + AA), and the heterogeneity analysis showed that $I^2 = 48\%$, P = 0.09, and there was no statistical heterogeneity among the studies. The results showed that the incidence of grade 0–2 thrombocytopenia in the course of IRI chemotherapy was lower in UGT1A1*6 wild-type (GG) than mutant type (GA + AA) [RR = 0.90, 95%CI (0.83, 0.98), P = 0.02], and the difference was statistically significant. (2) Grade 3–4: A total of six studies were included in the recessive gene model (GG vs. GA + AA), and the heterogeneity analysis showed that $I^2 = 25\%$, P = 0.25, and there was no statistical heterogeneity among the studies. The results showed that there was no significant difference in the

incidence of grade 3–4 thrombocytopenia between UGT1A1*6 wild-type (GG) and mutant type (GA + AA) during IRI chemotherapy [RR = 1.14, 95%CI (0.44, 2.92), P = 0.79], as shown in Figure 6. In summary, the polymorphisms of UGT1A1*6 gene were associated with the incidence of mild thrombocytopenia and the incidence of wild-type (GG) in cancer patients during IRI chemotherapy.

Hemoglobinia Five studies were included in the recessive gene model (GG vs. GA + AA) at grades 0–2 and 3-4, and the heterogeneity analysis was $I^2 = 0\%$, P = 0.46, $I^2 = 0\%$, and P = 1.00, respectively, suggesting that there was no statistical heterogeneity between the two groups. The results showed that



there was no significant difference in the incidence of hemoglobin reduction between UGT1A1*6 wild-type (GG) and mutant type (GA + AA) in grade 0–2 [RR = 1.02, 95%CI (0.91, 1.15), P = 0.75] and grade 3–4 [RR = 0.65, 95%CI (0.35, 1.23), P = 0.19] during IRI chemotherapy (P > 0.05), as shown in Figure 7. The results indicated that there was no correlation between UGT1A1*6 polymorphisms and hemoglobinia.

Correlation of UGT1A1*28 polymorphism with efficacy and toxicity of IRI

Efficacy evaluation

Similarly, disease response rate (RR = CR + PR) was selected to evaluate the relationship between UGT1A1*28 gene polymorphisms and IRI efficacy. Twelve studies with 1,025 people with cancer were included. We analysed the included studies using a recessive genetic model (TA6/6 vs. TA6/7 + TA7/7). Heterogeneity analysis showed that $I^2 = 42\%$, P = 0.06, and there was no statistical heterogeneity among the studies, and a fixed-effect model was used for analysis. The results showed that there was no significant difference in disease response rate [OR = 0.79, 95%CI (0.58, 1.08), P = 0.14] between UGT1A1*28 wild-type (TA6/6) and mutant type (TA6/7 + TA7/7) in the recessive gene model (P > 0.05), as shown in Figure 8. The results indicated that there was no correlation between UGT1A1*28 gene polymorphisms and IRI efficacy.

Toxicity

Diarrhea (1) Grade 0–2: A total of 15 studies were included in the recessive gene model (TA6/6 vs. TA6/7 + TA7/7), and the heterogeneity analysis showed that $I^2 = 81\%$, P < 0.00001, and there was statistical heterogeneity among the studies. The results showed that there was no statistically significant difference in the incidence of grade 0–2 diarrhea [RR = 1.07, 95%CI (0.84, 1.36), P = 0.58] between UGT1A1*28 wild-type (TA6/6) and mutant type (TA6/7 + TA7/7); (2) Grade 3–4: A total of 18 studies were included in the recessive gene model (TA6/6 vs. TA6/7 + TA7/7), and the heterogeneity analysis showed that $I^2 = 41\%$, P = 0.03, and there was no statistical heterogeneity among the studies. The results showed that UGT1A1*28 wild-type (TA6/6) had a lower incidence of grade 3–4 diarrhea than mutant type (TA6/7 + TA7/7) during IRI chemotherapy, and the difference was statistically significant [RR = 0.45, 95%CI (0.33, 0.61), P < 0.00001], as shown in Figure 9. Therefore, the polymorphisms of the UGT1A1*28 gene were associated with the incidence of grade 3–4 diarrhea in cancer patients during IRI chemotherapy, and the incidence of grade 3–4 diarrhea in cancer patients during IRI chemotherapy, and the incidence of wild-type (TA6/6) was lower.

Neutropenia Grades 0–2 and 3–4: The recessive gene model (TA6/6 vs. TA6/7 + TA7/7) was included in 14 studies in both groups, with heterogeneity analyses of $I^2 = 0\%$, P = 0.50 and $I^2 = 41\%$, P = 0.04, respectively, with no statistical heterogeneity between studies. The results showed that the incidence of grade 0–2 and grade 3–4 neutropenia in the course of IRI chemotherapy was significantly different from that of UGT1A1*28 wild-type (TA6/6) compared with mutant type (TA6/7 + TA7/7), respectively [RR = 1.21, 95%CI (1.09, 1.36), P = 0.0007] and [RR = 0.51, 95%CI (0.40, 0.67), P < 0.00001], respectively, as shown in Figure 10. The above results suggested that the polymorphism of UGT1A1*28 gene was correlated with the incidence of neutropenia in cancer patients during IRI chemotherapy, and the incidence of wild-type (TA6/6) is higher in mild neutropenia, and the incidence of mutant type (TA6/7 + TA7/7) is higher in severe neutropenia.

Leukopenia (1) Grade 0–2: A total of nine studies were included in the recessive gene model (TA6/6 vs. TA6/7 + TA7/7), and the heterogeneity analysis showed that it was $I^2 = 0\%$, P = 0.85, and there was no statistical heterogeneity among the studies. The results showed that UGT1A1*28 wild type (TA6/6) had a higher incidence of grade 0–2 leukopenia than mutant type (TA6/7 + TA7/7) [RR = 1.17, 95%CI (1.02, 1.35), P = 0.03], and the results were statistically different. (2) Grade 3–4: A total of 10 studies were included in the recessive gene model (TA6/6 vs. TA6/7 + TA7/7), and the heterogeneity analysis showed that $I^2 = 0\%$, P = 0.83, and there was no statistical heterogeneity among the studies. The results

Study or Subgroup	Evente	Total	Evente	Total	Woight	MH Random 95% CL	M H Random 95% Cl
2 1 1 Grade 0 2	Events	TULAI	Events	TULAI	weight	M-H, Kaluvili, 95% Cl	M-H, Rahuolii, 95% Ci
CUEN D 2017	25	4.4	15	10	1 106	0.05 (0.74, 1.22)	-
	60	66	11	20	4.470	1 65 [1 10 2 47]	
Chunloi Vu 2016	20	120	27	20	4.2.70	1.03 [1.10, 2.47] 0.42 [0.20 0.66]	
	20	67	21	10	9.170	1 70 [0.20, 0.00]	
HUO WU 2023	24	07	2	27	2.2.70	2 74 [4 60 A 64]	
	72	00	10	20	1 1 06	2.71 [1.30, 4.04]	
ULIVI 2012	12	49	6	20	4.470	1 31 [0.92, 2.11]	
DAN DV 2012	42	40	11	10	20%	0.67 (0.30, 1.16)	
MANG 0 2012	10	52	12	20	1 206	1 54 [1 07 2 22]	
WANG V 2010	40	102	14	20	26%	0.04 [1.07, 2.22]	
W/110 2013	25	28	4	10	3.3%	2 23 [1 03 4 82]	
VANG MD 2016	23	47	, R	19	20%	0.45 [0.17, 1.15]	
Vu Boi 2017	17	62	3	10	2.5%	1 74 [0.57 5 29]	
7HAGN X.I 2012	36	20	11	19	4 7%	1 51 11 02 2 201	
Subtotal (95% CI)	50	900		347	52.0%	1.19 [0.92, 1.54]	•
Total events	511	000	150	011	021070	110 [0102, 1101]	Ť
Heterogeneity: Tau² =	:0.16:Ch	d₹= 52	1 = 1b 88	3 (P ≤ 1	1 00001\·	I ² = 75%	
Test for overall effect:	7 = 1 33	(P = 0.2)	55, ar - 1 18)	- U - I		1 - 1070	
reaction overlain eneog.	2 = 1.00	0 = 0.1	. 0,				
2.1.2 Grade 3-4							
CHEN R 2017	11	44	5	18	3.0%	0.90 (0.36, 2.22)	
CHEN SJ 2018	6	66	q	20	3.0%	0.20 (0.08, 0.50)	
Chunlei Xu 2016	19	129	24	54	39%	0.33 [0.20, 0.55]	<u> </u>
HOU W(12023	11	67	5	10	3.2%	0.33 [0.14 0.75]	
HUAL 2019	15	93	12	27	3.7%		
IIA XY 2019		82		28	3.2%	0.34 [0.15, 0.77]	
LU YL 2012	6	48	4	9	2.7%	0.28 [0.10, 0.80]	
Minmin Li 2014	18	112	16	55	3.8%	0.55 [0.31, 1.00]	
PAN RY 2017	7	41	3	19	2.3%	1.08 [0.31, 3.73]	
WANG Q 2018	4	52	8	20	2.6%	0.19 (0.07, 0.57)	
WANG Y 2012	12	103	17	77	3.5%	0.53 [0.27, 1.04]	
WU Q 2013	3	28	6	10	2.4%	0.18 [0.05, 0.58]	
YANG MD 2016	6	47	8	18	3.0%	0.29 (0.12, 0.71)	
YIN H 2014	3	20	6	12	2.4%	0.30 [0.09, 0.98]	
Yu Bai 2017	3	62	3	19	1.8%	0.31 [0.07, 1.39]	
ZHAGN XJ 2012	3	38	7	18	2.3%	0.20 [0.06, 0.70]	
ZHANG Y 2014	7	34	1	19	1.2%	3.91 [0.52, 29,45]	
Subtotal (95% CI)		1066		433	48.0%	0.38 [0.29, 0.48]	♦
Total events	143		143			1798-1891 - Carolina - 1893 - 1896 -	
Heterogeneity: Tau ² =	0.07; Ch	i ^z = 21.	42, df = 1	6 (P = 1	0.16); I ² =	25%	
Test for overall effect:	Z=7.65	(P < 0.0	00001)		,,		
		1966		780	100.0%	0.69 [0.53, 0.89]	•
Total (95% CI)			293			eree foreet ereel	-
Total (95% Cl) Total events	654		200				
Total (95% CI) Total events Heterogeneity: Tau? -	654 0 39: Ch	$i^2 = 1.67$	1 57 df-	30 (P <	0.00001	111 = 87.96	
Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect	654 0.39; Ch 7 = 2 80	i ² = 164 (P = 0.0	4.57, df = 105)	30 (P <	0.00001); 1*= 82%	0.01 0.1 1 10 10
Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Test for subgroup dif	654 0.39; Ch Z = 2.80 erences	ii² = 164 (P = 0.0 Chi² =	4.57, df = 005) 39, 38, df	30 (P < = 1 (P ∘	: 0.00001 :: 0.00001); if = 82%	0.01 0.1 1 10 10 Favours G/G Favours G/A+A/A

showed that UGT1A1*28 wild-type (TA6/6) had a statistically significant difference in the incidence of grade 3–4 leukopenia during IRI chemotherapy compared with mutant type (TA6/7 + TA7/7) [RR = 0.64, 95%CI (0.47, 0.86), P = 0.004], as shown in Figure 11. In summary, the polymorphisms of UGT1A1*28 gene were associated with the incidence of leukopenia in cancer patients during IRI chemotherapy, and the incidence of wild type (TA6/6) was higher in mild leukopenia, and the incidence of mutant type (TA6/7 + TA7/7) was higher in severe leukopenia.

Thrombocytopenia (1) Grade 0–2: A total of seven studies were included in the recessive gene model (TA6/6 vs. TA6/7 + TA7/7), and the heterogeneity analysis showed that it was $I^2 = 46\%$, P = 0.10, and there was no statistical heterogeneity among the studies. The results showed that UGT1A1*28 wild-type (TA6/6) had a higher

incidence of grade 0–2 thrombocytopenia compared with mutant type (TA6/7 + TA7/7) [RR = 1.13, 95%CI (0.96, 1.33), P = 0.15], but there was no statistically significant difference in the results (P > 0.05); (2) Grade 3–4: A total of six studies were included in the recessive gene model (TA6/6 vs. TA6/7 + TA7/7), and the heterogeneity analysis showed that it was I² = 0%, P = 0.55, and there was no statistical heterogeneity among the studies. The results showed that the incidence of grade 3–4 thrombocytopenia in the course of IRI chemotherapy was lower in UGT1A1*28 wild-type (TA6/6) than mutant type (TA6/7 + TA7/7), and the difference was statistically significant [RR = 0.16, 95%CI (0.06, 0.42), P = 0.0002], as shown in Figure 12. In summary, the polymorphism of UGT1A1*28 gene was associated with the incidence of severe thrombocytopenia in cancer patients during IRI chemotherapy,

2.2.1 Grade 0-2 CHEN R 2017 Chunlei Xu 2016 HOU WJ 2023	Events	Total	Events	ota	VUOIMIT		
CHEN R 2017 Chunlei Xu 2016 HOU WJ 2023					weight	M-H, Kandom, 95% CI	Mi-H, Kandolli, 55% Ci
CHEN R 2017 Chunlei Xu 2016 HOU WJ 2023				4.0			
Chunlei Xu 2016 HOU WJ 2023	39	44	4	18	3.3%	3.99 [1.67, 9.53]	
HOU WJ 2023	40	129	21	54	4.6%	0.80 [0.52, 1.22]	
	18	67	3	10	2.8%	0.90 [0.32, 2.50]	
HUA L 2019	79	93	14	27	4.7%	1.64 [1.13, 2.38]	
JIA XY 2019	(1	82	17	28	4.9%	1.43 [1.05, 1.94]	<u> </u>
LU YE 2012	46	48	4	9	3.7%	2.16 [1.04, 4.49]	
PAN RY 2017	13	41	9	19	3.9%	0.67 [0.35, 1.29]	-T.
WANG Q 2018	37	52	8	20	4.2%	1.78 [1.01, 3.13]	
WU Q 2013	25	28	4	10	3.6%	2.23 [1.03, 4.82]	
YANG MD 2016	12	47	4	18	2.9%	1.15 [0.43, 3.10]	
Yu Bai 2017	14	62	0	19	0.7%	9.21 [0.57, 147.50]	
ZHAGN XJ 2012	32	38	13	18	4.9%	1.17 [0.85, 1.60]	
ZHANG CL 2019	14	27	6	17	3.7%	1.47 [0.70, 3.08]	
Subtotal (95% CI)		758		267	47.8%	1.40 [1.10, 1.79]	•
Total events	440		107				
Heterogeneity: Tau² = (0.09; Chi	i² = 25.	94, df = 1	2 (P = I	0.01); I ² =	54%	
Test for overall effect: 2	Z = 2.75 ((P = 0.0)	006)				
2.2.2 Grade 3-4							
CHEN R 2017	5	44	14	18	3.3%	0.15 [0.06, 0.35]	
Chunlei Xu 2016	18	129	7	54	3.4%	1.08 [0.48, 2.43]	
HOU WJ 2023	9	67	2	10	2.1%	0.67 [0.17, 2.67]	
HUA L 2019	17	93	10	27	3.9%	0.49 [0.26, 0.95]	
JIA XY 2019	11	82	11	28	3.7%	0.34 [0.17, 0.70]	
LU YL 2012	2	48	5	9	1.9%	0.07 [0.02, 0.33]	
Minmin Li 2014	12	112	9	55	3.5%	0.65 [0.29, 1.46]	
PAN RY 2017	5	41	2	19	1.8%	1.16 [0.25, 5.44]	
WANG Q 2018	15	52	12	20	4.2%	0.48 [0.28, 0.84]	
WANG Y 2012	29	103	21	77	4.4%	1.03 [0.64, 1.66]	+
WU Q 2013	5	28	6	10	3.1%	0.30 [0.12, 0.76]	
YANG MD 2016	7	47	4	18	2.7%	0.67 [0.22, 2.02]	
YIN H 2014	4	20	6	12	2.8%	0.40 [0.14, 1.14]	
Yu Bai 2017	11	62	3	19	2.5%	1.12 [0.35, 3.62]	
ZHAGN XJ 2012	6	38	5	18	2.8%	0.57 [0.20, 1.62]	— - †
ZHANG CL 2019	7	27	11	17	3.7%	0.40 [0.19, 0.83]	- - -
ZHANG Y 2014	4	34	5	19	2.5%	0.45 [0.14, 1.47]	
Subtotal (95% CI)		1027		430	52.2%	0.50 [0.37, 0.68]	•
Total events	167		133				
Heterogeneity: Tau ^z = (0.20; Chi	i ² = 32.	96, df = 1	6 (P = 1	0.007); I ř :	= 51%	
Test for overall effect: Z	Z = 4.45 ((P < 0.0	00001)				
Tatal (05% Ch		4705		607	100.00	0.0210.04 4.071	
Total (95% CI)	007	1/85	0.40	697	100.0%	0.83 [0.64, 1.07]	•
i otal events	607		240	00 /P			
Heterogeneity: Tau* = 1	0.32; Chi 7 - 4	r=111 (n=	1.88, at = 1 10	29 (P e	0.00001), i= / 4%	0.005 0.1 1 10 200
i est for overall effect: 2	∠ = 1.44 ((P = 0.1	(C)	4.05			Favours G/G Favours G/A+A/A

Forest map of Meta-analysis results of the correlation between UGT1A1*6 polymorphism and the incidence of granulocytopenia.

and the incidence of mutation (TA6/7 + TA7/7) was higher in severe thrombocytopenia.

Hemoglobinia At grades 0–2 and three to four, the recessive gene model (TA6/6 vs. TA6/7 + TA7/7) was included in five and three studies, respectively, and the heterogeneity analysis was $I^2 = 0\%$, P = 0.48, $I^2 = 0\%$, and P = 0.84, respectively, suggesting that there was no statistical heterogeneity between the two groups. The results showed that there was no significant difference in the incidence of grade 0–2 [RR = 1.09, 95%CI (0.96, 1.24), P = 0.18] and grade 3–4 [RR = 0.54, 95%CI (0.27, 1.09), P = 0.08] and grade 3–4 [RR = 0.54, 95%CI (0.27, 1.09), P = 0.08] in UGT1A1*28 wild-type (TA6/6) and mutant type (TA6/7 + TA7/7) during IRI chemotherapy (P > 0.05), as shown in Figure 13. The results indicated that there was no correlation between UGT1A1*28 gene polymorphisms and hemoglobin reduction.

Correlation between UGT1A1*6 and UGT1A1*28 double-locus polymorphisms and the efficacy and toxicity of IRI

Efficacy evaluation

The disease response rate (RR = CR + PR) was selected to evaluate the relationship between the polymorphism of UGT1A1*6 and UGT1A1*28 genes and the efficacy of IRI. Three studies were included, with 210 patients with cancer. We used double wild type (DW), single variant (SV) and double variant (DV) to analyze the included studies, respectively. The results showed that the disease remission rate of DW compared with SV during IRI chemotherapy for cancer [OR = 1.65, 95% CI

Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Random, 95% Cl	M-H. Random, 95% Cl
2.3.1 Grade 0-2							
CHEN R 2017	33	44	13	18	9.9%	1.04 (0.74, 1.45)	-+-
CHEN SJ 2018	56	66	12	20	9.5%	1.41 [0.97, 2.05]	
HOU WJ 2023	29	67	6	10	7.6%	0.72 [0.41, 1.28]	
LU YL 2012	46	48	4	9	6.3%	2.16 [1.04, 4.49]	
WANG Q 2018	44	52	15	20	10.4%	1.13 [0.85, 1.49]	+
Yu Bai 2017	19	62	5	19	5.5%	1.16 [0.50, 2.70]	
ZHAGN XJ 2012	27	38	7	18	7.3%	1.83 [0.99, 3.37]	
ZHANG CL 2019	15	27	14	17	9.3%	0.67 [0.45, 1.01]	
Subtotal (95% CI)		404		131	65.7%	1.13 [0.88, 1.44]	•
Total events	269		76				
Heterogeneity: Tau ²	= 0.07; Chi	² = 16.3	28, df = 7	(P = 0.	.02); I ² = 5	7%	
Test for overall effect	t: Z = 0.94 (P = 0.3	5)				
2.3.2 Grade 3-4							
CHEN R 2017	11	44	5	18	5.0%	0.90 [0.36, 2.22]	
CHEN SJ 2018	10	66	8	20	5.9%	0.38 [0.17, 0.83]	
HOU WJ 2023	3	67	0	10	0.8%	1.13 [0.06, 20.45]	
LU YL 2012	2	48	5	9	2.6%	0.07 [0.02, 0.33]	
WANG Q 2018	8	52	5	20	4.5%	0.62 [0.23, 1.66]	
YIN H 2014	3	20	5	12	3.4%	0.36 [0.10, 1.24]	
Yu Bai 2017	7	62	1	19	1.5%	2.15 [0.28, 16.35]	
ZHAGN XJ 2012	11	38	11	18	7.2%	0.47 [0.25, 0.88]	
ZHANG CL 2019	6	27	3	17	3.3%	1.26 [0.36, 4.38]	<u> </u>
Subtotal (95% CI)		424		143	34.3%	0.53 [0.33, 0.86]	
Total events	61		43				
Heterogeneity: Tau ²	= 0.20; Chi	² =13.3	39, df = 8	(P = 0.	10); I ^z = 4	.0%	
Test for overall effec	t: Z = 2.60 (P = 0.0	09)				
Total (95% CI)		828		274	100.0%	0.88 [0.67, 1.15]	•
Total events	330		119				
Heterogeneity: Tau ²	= 0.16; Chi	² = 44.9	58, df = 1	6 (P = 1	0.0002); P	² = 64%	
Test for overall effec	t: Z = 0.95 (P = 0.3	4)				U.UT U.T 1 10 100 Epyoure G/G. Epyoure G/A+A/A
Test for subaroup d	ifferences:	Chi² = 1	7.49. df=	1 (P =	0.006). I ^z	= 86.7%	Favours 0/0 Favours 0/A+A/A

(0.89, 3.05), P = 0.11], the disease remission rate of DW compared with DV [OR = 1.45, 95% CI (0.55, 3.84), P = 0.45] and the disease remission rate of SV compared with DV [OR = 0.56, 95% CI (0.21, 1.50), P = 0.25], none of the above three results were statistically significant (P > 0.05), suggesting that UGT1A1*6 and UGT1A1*28 dual sites have no correlation with IRI efficacy, as shown in Table 2.

Toxicity

Diarrhea (1) Grades 0–2: four studies were included. Metaanalysis showed that the incidence of grade 0 to two diarrhea in DW compared with SV during IRI chemotherapy for cancer was [RR = 0.60, 95% CI (0.27, 1.37), P = 0.23]; The incidence of grade 0–2 diarrhea in DW compared with DV was [RR = 0.78, 95%CI (0.16, 3.77), P = 0.76]; The incidence of grade 0 to two diarrhea in SV compared with DV was [RR = 1.58, 95%CI (1.15, 2.18), P = 0.005]; (2) Grades 3–4: Six studies were included. Meta-analysis showed that the incidence of grade 3–4 diarrhea in DW compared with SV during IRI chemotherapy was [RR = 0.48, 95% CI (0.30, 0.78), P =0.003]; The incidence of grade 3–4 diarrhea in DW compared with DV was [RR = 0.14, 95% CI (0.07, 0.25), P < 0.00001]; The incidence of grade 3 to 4 diarrhea in SV compared with DV was [RR = 0.33, 95% CI (0.19, 0.57), P < 0.0001]. The above results suggest that SV are more likely to have mild diarrhea, while the incidence of severe diarrhea is DV > SV > DW, as shown in Table 2.

Neutropenia (1) Grades 0-2: four studies were included. Metaanalysis showed that the incidence of grade 0-2 neutropenia in DW compared with SV during IRI chemotherapy was [RR = 0.93, 95%CI (0.56, 1.54), P = 0.77; The incidence of grade 0-2 neutropenia in DW compared with DV was [RR = 1.50, 95% CI (1.03, 2.19), P = 0.03]; The incidence of grade 0 to two neutropenia in SV compared with DV was [RR = 1.81, 95% CI (1.00-3.29), P = 0.05]; (2) Grade three to 4: six studies were included. Meta-analysis showed that the incidence of grade 3-4 neutropenia in DW compared with SV during IRI chemotherapy was [RR = 1.13, 95%CI (0.76, 1.69), P = 0.54]; The incidence of grade 3-4 neutropenia in DW compared with DV was [RR = 0.46, 95%CI (0.31, 0.69), P = 0.0002]; The incidence of grade 3-4 neutropenia in SV compared with DV was [RR = 0.36, 95% CI (0.23, 0.57), P < 0.0001]. These results suggested that DW was more likely to develop mild neutropenia, and DV are more likely to have severe neutropenia, as shown in Table 2.

Leukopenia Grades 0–2 and 3–4: two studies were included. The results of meta-analysis showed that there was no statistically significant difference in the incidence of leukopenia between DW and SV in grade 0–2 [RR = 1.04, 95%CI (0.76, 1.43), P = 0.81] and grade 3–4 [RR = 0.94, 95%CI (0.45, 1.98), P = 0.88]; There was no significant difference in the incidence of leukopenia between DW and DV in grade 0–2 [RR = 1.95, 95%CI (0.60, 6.37), P = 0.27] and

~	0/0		U/ATA	WA T			RISK Ratio
Study or Subgroup	Events	lotal	Events	lotal	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
2.4.1 Grade 0-2							
HOU WJ 2023	19	67	5	10	7.3%	0.57 [0.27, 1.17]	
LU YL 2012	47	48	9	9	13.2%	1.02 [0.88, 1.19]	+
WANG Q 2018	47	52	20	20	24.6%	0.92 [0.82, 1.03]	
WU Q 2013	27	28	8	10	9.9%	1.21 [0.88, 1.66]	
ZHAGN XJ 2012	34	38	18	18	20.8%	0.91 [0.79, 1.04]	
ZHANG CL 2019	20	27	17	17	17.9%	0.75 [0.59, 0.95]	_
Subtotal (95% CI)		260		84	93.7%	0.90 [0.83, 0.98]	•
Total events	194		77				
Heterogeneity: Chi ² =	= 9.66, df =	5 (P =	0.09); l ² :	= 48%			
Test for overall effect	: Z = 2.33 (P = 0.0	12)				
2.4.2 Grade 3-4							
HOU WJ 2023	1	67	1	10	1.5%	0.15 [0.01, 2.20]	•
LU YL 2012	1	48	0	9	0.7%	0.61 [0.03, 13.97]	· · · · · · · · · · · · · · · · · · ·
WANG Q 2018	5	52	0	20	0.6%	4.36 [0.25, 75.39]	
WU Q 2013	1	28	2	10	2.5%	0.18 [0.02, 1.76]	•
ZHAGN XJ 2012	4	38	0	18	0.6%	4.38 [0.25, 77.32]	
ZHANG CL 2019	1	27	0	17	0.5%	1.93 [0.08, 44.80]	·
Subtotal (95% CI)		260		84	6.3%	1.14 [0.44, 2.92]	
Total events	13		3				
Heterogeneity: Chi ² =	= 6.66, df =	5 (P =	0.25); l ² :	= 25%			
Test for overall effect	: Z = 0.27 ((P = 0.7	'9)				
Total (95% CI)		520		168	100.0%	0.92 [0.83, 1.02]	•
Total events	207		80				
Heterogeneity: Chi ² =	= 15.40, df	= 11 (F	= 0.16);	l ² = 299	%		
	and the large						0.2 0.5 1 2 5

FIGURE 6

Forest map of Meta-analysis results of the correlation between UGT1A1*6 polymorphism and the incidence of thrombocytopenia.

G/G G/A+A/A **Risk Ratio Risk Ratio** Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% Cl M-H, Fixed, 95% Cl 2.5.1 Grade 0-2 LU YL 2012 47 9 14.8% 1.02 [0.88, 1.19] 48 9 1.10 [0.83, 1.46] WANG Q 2018 20 20.3% 52 15 43 WU Q 2013 28 28 10 10 14.3% 1.00 [0.87, 1.15] ZHAGN XJ 2012 32 38 13 18 16.5% 1.17 [0.85, 1.60] ZHANG CL 2019 27 17.2% 0.80 [0.59, 1.08] 19 17 15 1.02 [0.91, 1.15] Subtotal (95% CI) 74 193 83.1% Total events 169 62 Heterogeneity: Chi² = 3.63, df = 4 (P = 0.46); l² = 0% Test for overall effect: Z = 0.32 (P = 0.75) 2.5.2 Grade 3-4 LU YL 2012 48 0 9 0.8% 0.61 [0.03, 13.97] 1 WANG Q 2018 9 52 5 20 6.8% 0.69 [0.26, 1.82] WU Q 2013 28 0 0.7% 1.14 [0.05, 25.89] 1 10 ZHAGN XJ 2012 6.4% 0.57 [0.20, 1.62] 6 38 5 18 ZHANG CL 2019 2 27 2 17 2.3% 0.63 [0.10, 4.06] Subtotal (95% CI) 193 74 16.9% 0.65 [0.35, 1.23] 19 12 Total events Heterogeneity: Chi² = 0.21, df = 4 (P = 1.00); l² = 0% Test for overall effect: Z = 1.32 (P = 0.19) Total (95% CI) 386 148 100.0% 0.96 [0.84, 1.10] Total events 188 74 Heterogeneity: Chi² = 6.60, df = 9 (P = 0.68); l² = 0% 0.2 0.5 ż <u>Ś</u> Test for overall effect: Z = 0.63 (P = 0.53) Favours G/G Favours G/A+A/A Test for subaroup differences: Chi² = 1.85. df = 1 (P = 0.17). I² = 45.9% FIGURE 7

Forest map of Meta-analysis results of the correlation between UGT1A1*6 polymorphism and the incidence of hemoglobin.



grade 3–4 [RR = 1.09, 95%CI (0.25, 4.72), P = 0.91]; There was no statistically significant difference in the incidence of leukopenia between SV and DV in grade 0–2 [RR = 2.01, 95%CI (0.60, 6.69), P = 0.26] and grade 3–4 [RR = 0.89, 95%CI (0.21, 3.78), P = 0.88]. The above results suggested that double-locus polymorphisms of UGT1A1*6 and UGT1A1*28 are not correlated with leukopenia, as shown in Table 2.

Sensitivity analysis

Due to the inclusion of 19 articles, the methodological quality of some clinical trials is not high. Therefore, the sensitivity analysis of the results of meta-analysis was carried out by removing one test each time and then re-statistic. There was no significant difference in the analysis results before and after the elimination of all studies, suggesting that all Meta-analysis results were stable.

Publication bias analysis

When the number of included studies ≥ 10 , the publication bias was tested by funnel plots, as recommended by the Cochrane Systematic Review Production Manual. We selected the disease response rates of UGT1A1*6 and UGT1A1*28 as indicators of publication bias for funnel plot statistics, and the results showed that the funnel graph was symmetrical, mainly concentrated in the middle and upper part, and only one study may be located on the outside of the inverted funnel plot due to factors such as poor design and poor research methods, and the overall result was no obvious publication bias, as shown in Figures 14A, B.

Discussion

Irinotecan (IRI) is a prodrug, which is converted into the active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) *in vivo* by futinylase, and its activity is 100–1,000 times stronger than

irinotecan. Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), on the other hand, converts SN-38 into inactive SN-38 glucuronide (SN38G), which is excreted from the bile, thereby protecting healthy cells from irinotecan toxicity (Bailly, 2019).

Single nucleotide polymorphism (SNP) is widely present in the human genome and is the main form of heritable variation in the DNA sequence of the human genome, which refers to the polymorphism of the DNA sequence caused by the variation of a single nucleotide at the genomic level, which is related to ethnic diversity, disease susceptibility, and differences in drug response (Walter et al., 2008). The UGT1A1 gene is located on human chromosome 2q37, and the polymorphism of UGT1A1*6 manifests itself as a mutation in exon 1211G > A, forming three genotypes: wild-type (G/G), heterozygous mutant (A/G), and homozygous mutant (A/A), which can lead to an alteration of the amino acid sequence at position 71 of the UGT1A1 enzyme (Arg→Gly), resulting in a decrease in enzyme activity (Kane 2012). In addition, the promoter region of UGT1A1 gene had polymorphisms, and the TATA cassette region contained 5-8 TA repeats, and the expression of UGT1A1 decreased with the increase of the number of TA repeats. The general population has 6/6TA repeats, while a minority have 7/7 or 6/7TA duplicates (Goon et al., 2016).

Due to the differences in genetic background, the differences in UGT1A1 mutation sites and mutation frequencies are important reasons for the obvious differences in the efficacy and incidence of adverse reactions between different cancer populations in Eastern and Western countries when receiving IRI treatment. Studies have shown that (Hirose et al., 2012) UGT1A1*28 has a mutation rate of only 1.2%-5.0% in Asians, which is much lower than in Africans (12%-27%) and Caucasians (5%-15%). Other studies (Etienne et al., 2015) have shown that UGT1A1* 28 mutation rates are 38%-45% and 29%-39% in the Americas and Caucasians, respectively, while UGT1A1*28 mutation rates are about 15%-18% and homozygous mutations are about 3% in Asian races. The US Food and Drug Administration (FDA) has included a risk warning of the possibility of severe neutropenia following IRI chemotherapy in the drug description. Although there are many studies, there are still different opinions on whether UGT1A1 can predict its

Study or Subarous	Evente	Total	Evonte	Total	Woight	M H Random 05% CL	M H Bandom 95% Cl
1 1 1 Grado 0 2	Events	rotal	Evenus	TUTAL	AAGINIU	m-n, random, 95% Cl	m-n, Kanuolli, 95% Ci
CUENID 2017	27	44	10	24	150	1 46 [4 00 0 07]	
	31	41	13	21	4.0%	1.40 [1.03, 2.07]	
CHEN 5J 2018	53	00	17	20	4.0%	1.35[1.01, 1.81]	
Chuniel Xu 2016	22	121	33	62	4.2%	0.34 [0.22, 0.53]	
HUU WJ 2023	10	32	15	45	3.4%	0.94 [0.48, 1.81]	
HUA L 2019	73	81	8	39	3.6%	4.39 [2.36, 8.18]	
JIA XY 2019	75	85	17	25	4.7%	1.30 [0.98, 1.72]	
JI CS 2010	46	51	8	13	4.2%	1.47 [0.94, 2.27]	
LU YL 2012	39	43	12	14	4.8%	1.06 [0.84, 1.34]	+
PAN RY 2017	25	42	9	18	3.9%	1.19 [0.70, 2.01]	
WANG Q 2018	46	57	14	15	4.9%	0.86 [0.72, 1.04]	
WANG Y 2012	18	125	13	55	3.5%	0.61 [0.32, 1.15]	
WU Q 2013	27	31	2	7	2.0%	3.05 [0.94, 9.91]	
YANG MD 2016	6	49	6	16	2.5%	0.33 [0.12, 0.87]	
Yu Bai 2017	15	61	5	20	2.8%	0.98 [0.41, 2.36]	
ZHAGN XJ 2012	38	47	8	9	4.7%	0.91 [0.69, 1.19]	
Subtotal (95% CI)	00	926	0	385	58.0%	1.07 [0.84, 1.36]	
Total events	520		190	500	2.5.6.10	[sisi, iiso]	ſ
Hotorogeneity: Tou ² –	0.15 Chi	Z - 74 (29 df - 1,	1/P < 0	00001\- 8	² − 91%	
Taet for overall effect:	7 - 0.657	(D = 0.9.)	50, ut – 14 :01	τų × 0.	00001),1	- 01 /0	
restion overall ellect.	2-0.55 ((r = 0.5	0)				
1 1 2 Grado 3 <i>1</i>							
OUEN D 2047		44		24	2.200	0.00 10.00 0.751	
	4	41	8	21	2.2%	0.26 [0.09, 0.75]	
CHEN SJ ZU18		60	9	26	2.8%	0.34 [0.14, 0.81]	
Chuniel Xu 2016	17	121	26	62	3.9%	0.34 [0.20, 0.57]	
HOU WJ 2023	5	32	12	45	2.6%	0.59 [0.23, 1.50]	
HUA L 2019	27	81	12	39	3.8%	1.08 [0.62, 1.90]	
IIA VV 2010	10	85	8	25	2.9%	0.37 [0.16, 0.83]	
JIA AT 2019	10	00			2 201	0 0 5 10 00 0 7 5	
JI CS 2010	5	51	5	13	2.2%	0.25 [0.09, 0.75]	
JI CS 2010 LU YL 2012	10 5 4	51 43	5 2	13 14	2.2% 1.4%	0.25 (0.09, 0.75) 0.65 (0.13, 3.18)	
JI CS 2010 LU YL 2012 Minmin Li 2014	10 5 4 16	51 43 109	5 2 18	13 14 58	2.2% 1.4% 3.7%	0.25 (0.09, 0.75) 0.65 (0.13, 3.18) 0.47 (0.26, 0.86)	
JI CS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017	10 5 4 16 2	51 43 109 42	5 2 18 4	13 14 58 18	2.2% 1.4% 3.7% 1.3%	0.25 (0.09, 0.75) 0.65 (0.13, 3.18) 0.47 (0.26, 0.86) 0.21 (0.04, 1.07)	
JI CS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017 WANG Q 2018	10 5 4 16 2 11	51 43 109 42 57	5 2 18 4 1	13 14 58 18 15	2.2% 1.4% 3.7% 1.3% 1.0%	0.25 (0.09, 0.75) 0.65 (0.13, 3.18) 0.47 (0.26, 0.86) 0.21 (0.04, 1.07) 2.89 (0.41, 20.69)	
JI CS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017 WANG Q 2018 WANG Y 2012	10 5 4 16 2 11 19	51 43 109 42 57 125	5 2 18 4 1 10	13 14 58 18 15 55	2.2% 1.4% 3.7% 1.3% 1.0% 3.3%	0.25 [0.09, 0.75] 0.65 [0.13, 3.18] 0.47 [0.26, 0.86] 0.21 [0.04, 1.07] 2.89 [0.41, 20.69] 0.84 [0.42, 1.68]	
U CS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017 WANG Q 2018 WANG Y 2012 WU Q 2013	10 5 16 2 11 19 4	51 43 109 42 57 125 31	5 2 18 4 1 10 5	13 14 58 18 15 55 7	2.2% 1.4% 3.7% 1.3% 1.0% 3.3% 2.4%	0.25 [0.09, 0.75] 0.65 [0.13, 3.18] 0.47 [0.26, 0.86] 0.21 [0.04, 1.07] 2.89 [0.41, 20.69] 0.84 [0.42, 1.68] 0.18 [0.06, 0.50]	
MARE 2013 LU CS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017 WANG Q 2018 WANG Y 2012 WU Q 2013 YANG MD 2016	10 5 4 16 2 11 19 4 4	51 43 109 42 57 125 31 49	5 2 18 4 10 5 6	13 14 58 18 15 55 7 16	2.2% 1.4% 3.7% 1.3% 1.0% 3.3% 2.4% 2.1%	0.25 [0.09, 0.75] 0.65 [0.13, 3.18] 0.47 [0.26, 0.86] 0.21 [0.04, 1.07] 2.89 [0.41, 20.69] 0.84 [0.42, 1.68] 0.18 [0.06, 0.50] 0.22 [0.07, 0.68]	
MART 2013 LU CS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017 WANG Q 2018 WANG Y 2012 WU Q 2013 YANG MD 2016 YIN H 2014	10 5 4 16 2 11 19 4 4 4	51 43 109 42 57 125 31 49 52	5 2 18 4 10 5 6 5	13 14 58 18 15 55 7 16 16	2.2% 1.4% 3.7% 1.3% 1.0% 3.3% 2.4% 2.1% 2.0%	0.25 [0.09, 0.75] 0.65 [0.13, 3.18] 0.47 [0.26, 0.86] 0.21 [0.04, 1.07] 2.89 [0.41, 20.69] 0.84 [0.42, 1.68] 0.18 [0.06, 0.50] 0.22 [0.07, 0.68] 0.25 [0.07, 0.81]	
JI CS 2010 JI CS 2010 Minmin Li 2014 PAN RY 2017 WANG Q 2018 WANG Y 2012 WU Q 2013 YANG MD 2016 YIN H 2014 Yu Bai 2017	10 5 4 16 2 11 19 4 4 4	51 43 109 42 57 125 31 49 52 61	5 2 18 4 10 5 6 5 2	13 14 58 18 15 55 7 16 16 20	2.2% 1.4% 3.7% 1.3% 1.0% 3.3% 2.4% 2.1% 2.0% 1.3%	0.25 (0.09, 0.75) 0.65 (0.13, 3.18) 0.47 (0.26, 0.86) 0.21 (0.04, 1.07) 2.89 (0.41, 20.69) 0.84 (0.42, 1.68) 0.18 (0.06, 0.50) 0.22 (0.07, 0.68) 0.25 (0.07, 0.81) 0.66 (0.13, 3.32)	
JI CS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017 WANG Q 2018 WANG Y 2012 WU Q 2013 YANG MD 2016 YIN H 2014 YU Bai 2017 ZHAGN XJ 2012	10 5 4 16 2 11 19 4 4 4 4 4 9	51 43 109 42 57 125 31 49 52 61 47	5 2 18 4 10 5 6 5 2 1	13 14 58 18 15 55 7 16 16 20 9	2.2% 1.4% 3.7% 1.3% 1.0% 3.3% 2.4% 2.1% 2.0% 1.3% 1.0%	0.25 (0.09, 0.75) 0.65 (0.13, 3.18) 0.47 (0.26, 0.86) 0.21 (0.04, 1.07) 2.89 (0.41, 20.69) 0.84 (0.42, 1.68) 0.18 (0.06, 0.50) 0.22 (0.07, 0.68) 0.25 (0.07, 0.81) 0.66 (0.13, 3.32) 1.72 (0.25 11.98)	
JI CS 2010 LU YL 2012 Minmin LI 2014 PAN RY 2017 WANG Q 2018 WANG Y 2012 WU Q 2013 YANG MD 2016 YIN H 2014 Yu Bai 2017 ZHAGO XJ 2012 ZHAGO X 2014	10 5 4 16 2 11 19 4 4 4 4 9 7	51 43 109 42 57 125 31 49 52 61 47 77	5 2 18 4 10 5 6 5 2 1 4	13 14 58 18 15 55 7 16 16 20 9 25	2.2% 1.4% 3.7% 1.0% 3.3% 2.4% 2.1% 2.0% 1.3% 1.0% 2.1%	0.25 [0.09, 0.75] 0.65 [0.13, 3.18] 0.47 [0.26, 0.86] 0.21 [0.04, 1.07] 2.89 [0.41, 20.69] 0.84 [0.42, 1.68] 0.18 [0.06, 0.50] 0.22 [0.07, 0.68] 0.25 [0.07, 0.81] 0.66 [0.13, 3.32] 1.72 [0.25, 11.98] 0.57 [0.18, 1.79]	
MART 2013 JICS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017 WANG Q 2018 WANG Y 2012 WU Q 2013 YANG MD 2016 YIN H 2014 Yu Bai 2017 ZHAGN XJ 2012 ZHAGN XJ 2012 ZHANG Y 2014	10 5 4 16 2 11 19 4 4 4 9 7	51 43 109 42 57 125 31 49 52 61 47 77 77 1164	5 2 18 4 10 5 6 5 2 1 4	13 14 58 18 15 55 7 16 16 20 9 25 25	2.2% 1.4% 3.7% 1.0% 3.3% 2.4% 2.1% 2.0% 1.3% 1.0% 2.1% 2.1%	0.25 [0.09, 0.75] 0.65 [0.13, 3.18] 0.47 [0.26, 0.86] 0.21 [0.04, 1.07] 2.89 [0.41, 20.69] 0.84 [0.42, 1.68] 0.18 [0.06, 0.50] 0.22 [0.07, 0.68] 0.25 [0.07, 0.81] 0.66 [0.13, 3.32] 1.72 [0.25, 11.98] 0.47 [0.18, 1.78] 0.45 [0.33, 0.64]	
MART 2019 JL CS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017 WANG Q 2018 WU Q 2013 YANG MD 2016 YIN H 2014 Yu Bai 2017 ZHAGN XJ 2012 ZHANG Y 2014 Subtotal (95% CI) Total exerts	10 5 4 12 11 19 4 4 4 4 9 7	51 43 109 42 57 125 31 49 52 61 47 77 1164	5 2 18 4 1 10 5 6 5 2 1 4	13 14 58 15 55 7 16 16 20 9 25 484	2.2% 1.4% 3.7% 1.3% 1.0% 2.4% 2.1% 2.0% 1.3% 1.0% 2.1% 42.0%	0.25 [0.09, 0.75] 0.65 [0.13, 3.18] 0.47 [0.26, 0.86] 0.21 [0.04, 1.07] 2.89 [0.41, 20.69] 0.84 [0.42, 1.68] 0.18 [0.06, 0.50] 0.22 [0.07, 0.68] 0.25 [0.07, 0.81] 0.66 [0.13, 3.32] 1.72 [0.25, 11.98] 0.57 [0.18, 1.78] 0.45 [0.33, 0.61]	
DI CS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017 WANG Q 2018 WANG Y 2012 WU Q 2013 YANG MD 2016 YIN H 2014 Yu Bai 2017 ZHAGN XJ 2012 ZHANG Y 2014 Subtotal (95% CI) Total events	10 5 4 16 2 11 19 4 4 4 4 9 7 7 159 0.15:05	51 43 109 42 57 125 31 49 52 61 47 77 1164	5 2 18 4 1 10 5 6 5 2 1 4 4 3138	13 14 58 15 55 7 16 16 20 9 25 484	2.2% 1.4% 3.7% 1.3% 1.0% 2.4% 2.1% 2.0% 1.3% 1.0% 2.1% 42.0%	0.25 (0.09, 0.75) 0.65 (0.13, 3.18) 0.47 (0.26, 0.86) 0.21 (0.04, 1.07) 2.89 (0.41, 20.69) 0.84 (0.42, 1.68) 0.18 (0.06, 0.50) 0.22 (0.07, 0.68) 0.25 (0.07, 0.81) 0.66 (0.13, 3.32) 1.72 (0.25, 11.98) 0.57 (0.18, 1.78) 0.45 (0.33, 0.61)	
UI CS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017 WANG Q 2018 WANG Y 2012 WU Q 2013 YANG MD 2016 YIN H 2014 Yu Bai 2017 ZHAGN XJ 2012 ZHAGN XJ 2012 ZHAGN Z 2014 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect:	10 4 16 2 11 19 4 4 4 4 9 7 7 159 0.16; Chi Z = 5.20 (53 51 43 109 42 57 125 31 49 52 61 47 77 1164 ₹ = 29.1 (P < 0.0	5 2 18 4 1 0 5 6 5 2 1 4 4 138 04, df = 17 0001)	13 14 58 18 15 55 7 16 16 20 25 484 7 (P = 0.	2.2% 1.4% 3.7% 1.3% 1.0% 2.4% 2.1% 2.0% 1.3% 1.0% 2.1% 42.0% 03); ² = 4	0.25 [0.09, 0.75] 0.65 [0.13, 3.18] 0.47 [0.26, 0.86] 0.21 [0.04, 1.07] 2.89 [0.41, 20.69] 0.84 [0.42, 1.68] 0.18 [0.06, 0.50] 0.22 [0.07, 0.68] 0.25 [0.07, 0.81] 0.66 [0.13, 3.32] 1.72 [0.25, 11.98] 0.57 [0.18, 1.78] 0.45 [0.33, 0.61]	
JI CS 2010 JI CS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017 WANG Q 2018 WANG Y 2012 WU Q 2013 YANG MD 2016 YIN H 2014 YU Bai 2017 ZHAGN XJ 2012 ZHAGN XJ 2012 ZHANG Y 2014 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Total (95% CI)	10 4 16 2 11 19 4 4 4 4 9 7 7 159 0.16; Chi Z = 5.20 (2000 2000 2000 2000 2000 2000 2000 2000 2000 2000	5 2 18 4 1 1 5 6 5 2 1 4 4 138 04, df = 1 0001)	13 14 58 18 15 55 7 16 16 20 9 25 484 7 (P = 0.	2.2% 1.4% 3.7% 1.3% 1.0% 3.3% 2.4% 2.1% 2.0% 1.3% 1.0% 2.1% 42.0% 03); ² = 4	0.25 [0.09, 0.75] 0.65 [0.13, 3.18] 0.47 [0.26, 0.86] 0.21 [0.04, 1.07] 2.89 [0.41, 20.69] 0.84 [0.42, 1.68] 0.18 [0.06, 0.50] 0.22 [0.07, 0.68] 0.25 [0.07, 0.81] 0.66 [0.13, 3.32] 1.72 [0.25, 11.98] 0.57 [0.18, 1.78] 0.45 [0.33, 0.61] 1%	
UI CS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017 WANG Q 2018 WANG Y 2012 WU Q 2013 YANG MD 2016 YIN H 2014 Yu Bai 2017 ZHAGN XJ 2012 ZHAGN XJ 2012 ZHAGN GY 2014 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Total ovents	10 4 16 2 11 19 4 4 4 9 7 7 159 0.16; Chi Z = 5.20 (53 43 109 42 57 125 31 49 52 67 49 52 67 47 77 1164 ₹ = 29,1 (P < 0.0 2090	5 2 18 4 1 100 5 6 5 2 1 4 138 04, df = 17 0001)	13 14 58 15 55 7 16 20 9 25 484 7 (P = 0. 869	2.2% 1.4% 3.7% 1.3% 1.0% 2.4% 2.1% 2.0% 1.0% 2.1% 42.0% 03); ² = 4 100.0%	0.25 [0.09, 0.75] 0.65 [0.13, 3.18] 0.47 [0.26, 0.86] 0.21 [0.04, 1.07] 2.89 [0.41, 20.69] 0.84 [0.42, 1.68] 0.18 [0.06, 0.50] 0.22 [0.07, 0.68] 0.25 [0.07, 0.81] 0.66 [0.13, 3.32] 1.72 [0.25, 11.98] 0.57 [0.18, 1.78] 0.45 [0.33, 0.61] 1%	
ANN 12013 JI CS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017 WANG Q 2018 WU Q 2013 YANG MD 2016 YIN H 2014 Yu Bai 2017 ZHAGN XJ 2012 ZHANG Y 2014 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Total events	10 4 16 2 11 19 4 4 4 4 9 7 7 159 0.16; Chi Z = 5.20 (889	53 43 109 42 57 125 31 49 52 61 47 77 1164 F = 29.1 (P < 0.0 2090 F = 142	5 2 18 4 1 10 5 6 5 2 1 4 138 04, df = 17 0001)	13 14 58 15 55 7 16 16 20 9 25 484 7 (P = 0. 869	2.2% 1.4% 3.7% 1.3% 1.0% 2.4% 2.1% 2.0% 1.3% 1.0% 2.1% 42.0% 03); ² = 4	0.25 [0.09, 0.75] 0.65 [0.13, 3.18] 0.47 [0.26, 0.86] 0.21 [0.04, 1.07] 2.89 [0.41, 20.69] 0.84 [0.42, 1.68] 0.18 [0.06, 0.50] 0.22 [0.07, 0.68] 0.25 [0.07, 0.81] 0.66 [0.13, 3.32] 1.72 [0.25, 11.98] 0.57 [0.18, 1.78] 0.45 [0.33, 0.61] 1% 0.74 [0.60, 0.92]	
SIGAT 2019 JI CS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017 WANG Q 2018 WANG Q 2018 WU Q 2013 YANG MD 2016 YIN H 2014 Yu Bai 2017 ZHAGN XJ 2012 ZHANG Y 2014 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Total events Heterogeneity: Tau ² =	10 4 16 2 11 19 4 4 4 4 4 9 7 7 159 0.16; Chi Z= 5.20 (689 0.24; Chi	60 43 109 42 57 125 31 49 52 61 47 77 1164 ² = 29,1 ² = 29,1 ² = 29,1 ² = 29,1 ² = 29,1 ² = 29,1 ² = 20,1 ² = 20,2 ² = 20,1 ² = 2	5 2 18 4 10 5 6 5 2 1 4 138 04, df = 1 0001) 318 .54, df = 3	13 14 58 15 55 7 16 20 9 25 484 7 (P = 0. 869 32 (P < 1	2.2% 1.4% 3.7% 1.3% 1.0% 3.3% 2.4% 2.0% 1.3% 1.0% 2.1% 42.0% 03); ² = 4 100.0%	0.25 (0.09, 0.75) 0.65 (0.13, 3.18) 0.47 (0.26, 0.86) 0.21 (0.04, 1.07) 2.89 (0.41, 20.69) 0.84 (0.42, 1.68) 0.18 (0.06, 0.50) 0.22 (0.07, 0.68) 0.25 (0.07, 0.81) 0.66 (0.13, 3.32) 1.72 (0.25, 11.98) 0.57 (0.18, 1.78) 0.45 (0.33, 0.61) 1% 0.74 (0.60, 0.92) F = 79%	
JI CS 2010 LU YL 2012 Minmin Li 2014 PAN RY 2017 WANG Q 2018 WANG Y 2012 WU Q 2013 YANG MD 2016 YIN H 2014 Yu Bai 2017 ZHAGN XJ 2012 ZHAGN XJ 2012 ZHANG Y 2014 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Total events Heterogeneity: Tau ² = Test for overall effect: Total events Heterogeneity: Tau ² = Test for overall effect:	10 4 16 2 11 19 4 4 4 4 4 9 7 7 159 0.16; Chi Z = 5.20 (689 0.24; Chi Z = 2.68 (51 43 109 42 57 125 31 47 77 1164 ² = 29.0 81 47 77 1164 ² = 29.0 2090 ² = 1488 (P = 0.0	5 2 18 4 10 5 6 5 2 1 4 138 04, df = 1 0001) 318 .54, df = 1	13 14 58 15 55 7 16 16 20 9 25 484 7 (P = 0. 869 32 (P < 1	2.2% 1.4% 3.7% 1.3% 1.0% 3.3% 2.4% 2.1% 2.0% 1.3% 1.0% 2.1% 42.0% 03); ² = 4 100.0% 0.00001);	0.25 [0.09, 0.75] 0.65 [0.13, 3.18] 0.47 [0.26, 0.86] 0.21 [0.04, 1.07] 2.89 [0.41, 20.69] 0.84 [0.42, 1.68] 0.18 [0.06, 0.50] 0.22 [0.07, 0.68] 0.25 [0.07, 0.81] 0.66 [0.13, 3.32] 1.72 [0.25, 11.98] 0.57 [0.18, 1.78] 0.45 [0.33, 0.61] 1% 0.74 [0.60, 0.92] P = 79% F = 79%	0.05 0.2 1 5 20 Favours TA6/6 Favours TA6/7+TA7/7

chemotherapy efficacy and toxicity. Therefore, this article uses metaanalysis to systematically evaluate the relationship between UGT1A1*6 and UGT1A1*28 polymorphisms and IRI efficacy and related toxicity, so as to provide more reliable evidencebased medical evidence for clinical treatment.

In this in-depth study, we systematically analyzed the impact of UGT1A1*6 and UGT1A1*28 polymorphisms on the efficacy and toxicity of irinotecan (IRI) chemotherapy in Chinese cancer patients. The study employed a meta-analysis approach to comprehensively assess multiple research findings, aiming to provide a scientific basis for personalized treatment in Chinese cancer patients. In terms of efficacy assessment, our results showed that under the recessive genetic model, individuals carrying UGT1A1*6, UGT1A1*28, or both variations (double variants) did not exhibit significant differences in response

rate (RR). This finding suggests that UGT1A1 gene polymorphisms cannot effectively predict the efficacy of IRI chemotherapy in the Chinese cancer patient population. This conclusion is consistent with previous research by Chen et al. (2017b), further reinforcing the view that UGT1A1 polymorphisms are not directly associated with IRI efficacy. In terms of toxicity analysis, we found that the standard dose of IRI (180 mg/m²) may be insufficient to achieve the desired therapeutic effect for patients with wild-type and heterozygous mutations. Therefore, we recommend conducting genetic typing before initiating chemotherapy to guide the exploration of personalized dosing (Zhou CF et al., 2013). Specifically, for patients carrying the wild-type alleles of UGT1A1*28 and UGT1A1*6, a moderate increase in the IRI dose may lead to better clinical outcomes without significantly increasing the risk of diarrhea and

Study of Subgroup	Events	rotal	Evenus	Total	weight	m-n, Random, 95% Cl	M-H, Kand	om, 95% Cl
1.2.1 Grade 0-2								
CHEN R 2017	29	41	14	21	5.0%	1.06 [0.74, 1.52]		
Chunlei Xu 2016	39	121	22	62	4.7%	0.91 [0.59, 1.39]	_	
HOU WJ 2023	12	32	12	45	3.5%	1.41 [0.73, 2.72]		
HUA L 2019	68	81	27	39	5.5%	1.21 [0.96, 1.53]		-
JIA XY 2019	76	85	17	25	5.3%	1.31 [1.00, 1.74]		-
II CS 2010	28	51	5	13	3.2%	1.43 [0.69, 2.97]	-	
LU YL 2012	40	43	12	14	5.5%	1.09 [0.86, 1.36]	-	₽ -
PAN RY 2017	23	42	5	18	3.0%	1.97 [0.89, 4.36]		
VANG Q 2018	38	57	5	15	3.2%	2.00 [0.96, 4.19]		
NU Q 2013	24	31	2	7	1.8%	2.71 [0.83, 8.88]	-	
YANG MD 2016	15	49	2	16	1.5%	2.45 [0.63, 9.57]	_	
ru Bai 2017	10	61	4	20	2.2%	0.82 [0.29, 2.33]		<u> </u>
ZHAGN XJ 2012	39	47	6	9	4.4%	1.24 [0.77, 2.01]	-	-
ZHANG CL 2019	23	28	5	10	3.6%	1.64 [0.86, 3.13]	-	
Subtotal (95% CI)		769		314	52.5%	1.21 [1.09, 1.36]		•
Fotal events	464		138					
Heterogeneity: Tau² =	0.00: Chi	² =12.3	31, df = 13	P = 0	50); I ² = 0	%		
Test for overall effect:	Z= 3.41 (P = 0.0	007)		//. 0			
	-		,					
1.2.2 Grade 3-4								
CHEN R 2017	12	41	7	21	3.1%	0.88 [0.41, 1.90]		<u> </u>
Chunlei Xu 2016	15	121	10	62	3.2%	0.77 (0.37, 1.61)		<u></u>
HOU WU 2023	4	32	8	45	2.0%	0.70 [0.23, 2.14]		
HUA L 2019	13	81	12	39	3.4%	0.52 [0.26, 1.04]		ł
IIA XY 2019	ģ	85	.2	25	2.8%	0.33 [0.14 0.77]		
ILCS 2010	23	51	8	13	4.2%	0 73 10 43 1 241		+
U YL 2012	3	43	2	14	1 1 96	0.49 (0.09.2.63)		
Minmin Li 2014	11	109	10	58	3.0%	0.59 (0.26, 1.30)		-
PAN RY 2017	0	42	7	18	0.4%	0.03 (0.00, 0.49)	4	
WANG Q 2018	19	57	10	15	4.2%	0.50 (0.30, 0.83)		
MANG Y 2012	34	125	16	55	4 3%	0.94 (0.57, 1.55)		
MILO 2013	7	31	5	7	3.0%	0.32 [0.04 0.71]		
ANG MD 2016	4	49	10	16	2 3 96	0.13 (0.05, 0.36)		
/IN H 2014	4	52	6	16	2.0%	0.10[0.03, 0.30]		
/u Bai 2017	11	61	3	20	1 0 %	1 20 10 27 2 001		
7HAGN X I 2012	0	47	2	20 0	2.0%	0.51 [0.17, 1.60]		L
THANG CL 2012	0	47 29	5	9 10	2.070	0.31 [0.17, 1.30]		4
TUANG V 2014	0	20 77	U R	25	2.370	0.30 [0.13, 0.90]		Ļ
Subtotal (05% Ch	0	1132	0	469	47 5%	0.43 [0.17, 1.13]	.	
Fotol overte	100	TJZ	106	400	41.370	0.51 [0.40, 0.07]	•	
i utar eventis Jotorogonoitu: Tou? –	190	z - 201	130 70 df = 43	/D = 0	0.43 - 18 4	4.07		
heterogeneity. Tau* =	0.12, CNI	ι − 2ŏ., Έ ~ 0.0	າສຸບ(=17 10004 \	(== 0.	04), 17 = 4	1.70		
resciul overall ellect.	Z = 0.01 (,F 5 0.0	0001)					
fotal (95% CI)		1901		782	100.0%	0.84 [0.69 1.02]	4	
Fotal evente	864	1001	274	102	100.070	0.04 [0.03, 1.02]	•	
Hotorogonoity: Tou ² –	0.16.06	z = 02 4	274 10 df− 01	(P < 0	000013-8	r - 67%	<u> </u>	
Fact for overall offect	7 - 1 76 /	р — рэ. р — п п	io, ui – o i 19)	Q 50.	00001), 1	- 07.0	0.01 0.1	1 10 100
	z= 1.00 (, = 0.0					Favours TA6/6	Favours TA6/7+TA7/7
Feet for exharoun diff	oroncoe.	Chi≧ − 1	26 32 Af-	:1(P <	11 11111111111111	f = 0.7796		

hematological toxicity. In fact, previous studies (Etienne-Grimaldi MC et al., 2015) have determined the maximum tolerated dose of IRI under a FOLFIRI regimen guided by genetic typing, with 420 mg/m² for patients with the 6/6 wild-type and 370 mg/m² for those with the 6/7 variant. However, it is worth noting that the IRI doses in the studies included in this meta-analysis generally remained at the standard dose level (180 mg/m²), administered once daily *via* intravenous infusion. Furthermore, our study revealed associations between UGT1A1*6 and UGT1A1*28 polymorphisms and various severe toxic events during IRI chemotherapy. Specifically, these polymorphisms are associated with an increased risk of grade 3–4 thrombocytopenia. However, the incidence of these toxic reactions is relatively low in patients with the wild-type alleles (GG and TA6/6). In particular, patients with the UGT1A1*6 wild-type (GG) have a lower incidence of grade

0-2 thrombocytopenia but a higher incidence of grade 0-2 neutropenia. In contrast, patients with the UGT1A1*28 wildtype (TA6/6) have a higher incidence of grade 0-2 neutropenia and grade 0-2 leukopenia. Additionally, we observed that among patients with double variants (DV) and IRI toxicity, those with double wild-type alleles (DW) are more prone to grade 0-2 neutropenia, those with single variants (SV) are more prone to grade 0-2 diarrhea, and those with double variants (DV) are more prone to grade 3-4 neutropenia. However, these polymorphisms are not directly associated with the occurrence of leukopenia. Among all the analysis results, we also found a correlation between UGT1A1 polymorphisms and hemoglobin reduction. In summary, this study demonstrates that UGT1A1*6 and UGT1A1*28 polymorphisms can serve as important molecular markers for predicting varying degrees of toxicity induced by IRI chemotherapy in Chinese cancer patients,

Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
1.3.1 Grade 0-2							
CHEN R 2017	31	41	15	21	10.1%	1.06 [0.77, 1.46]	+
CHEN SJ 2018	51	60	18	26	12.8%	1.23 [0.93, 1.62]	+
HOU WJ 2023	16	32	20	45	8.5%	1.13 [0.70, 1.81]	
JI CS 2010	33	51	6	13	4.9%	1.40 [0.75, 2.61]	
LU YL 2012	40	43	12	14	9.2%	1.09 [0.86, 1.36]	+
WANG Q 2018	47	57	10	15	8.1%	1.24 [0.85, 1.80]	+
Yu Bai 2017	18	61	6	20	4.6%	0.98 [0.45, 2.13]	
ZHAGN XJ 2012	31	47	3	9	2.6%	1.98 [0.77, 5.10]	
ZHANG CL 2019	21	28	8	10	6.0%	0.94 [0.64, 1.37]	
Subtotal (95% CI)		420		173	66.8%	1.17 [1.02, 1.35]	•
Total events	288		98				
Heterogeneity: Chi ²	= 4.03, df =	8 (P =	0.85); l² =	0%			
Test for overall effec	t: Z = 2.18 (P = 0.0	3)				
1.3.2 Grade 3-4							
CHEN R 2017	10	41	6	21	4.0%	0.85 (0.36, 2.03)	
CHEN SJ 2018	9	60	8	26	5.7%	0.49 [0.21, 1.12]	
HOU WJ 2023	1	32	2	45	0.8%	0.70 [0.07, 7.43]	
JI CS 2010	18	51	7	13	5.7%	0.66 [0.35, 1.23]	
LU YL 2012	3	43	2	14	1.5%	0.49 [0.09, 2.63]	
WANG Q 2018	10	57	5	15	4.0%	0.53 [0.21, 1.31]	
YIN H 2014	6	52	5	16	3.9%	0.37 [0.13, 1.05]	
Yu Bai 2017	7	61	1	20	0.8%	2.30 [0.30, 17.54]	
ZHAGN XJ 2012	16	47	6	9	5.1%	0.51 [0.28, 0.94]	
ZHANG CL 2019	7	28	2	10	1.5%	1.25 [0.31, 5.05]	
Subtotal (95% CI)		472		189	33.2%	0.64 [0.47, 0.86]	•
Total events	87		44				
Heterogeneity: Chi ²	= 5.09, df =	9 (P =	0.83); l² =	0%			
Test for overall effec	t: Z = 2.89 (P = 0.0	04)				
Total (95% CI)		892		362	100.0%	0.99 [0.87, 1.13]	•
Total events	375		142				
Heterogeneity: Chi ²	= 23.86, df=	= 18 (P	= 0.16); P	² = 25%			
Test for overall effec	t: Z = 0.11 (P = 0.9	1)				U.UZ U.1 1 10 50
Test for subaroup d	ifferences: (Chi ² = 1	12.53. df=	: 1 (P =	0.0004). I	²= 92.0%	Favours 1A6/6 Favours 1A6/7+1A777

particularly in predicting severe toxic events such as severe diarrhea and severe neutropenia. Meanwhile, these polymorphisms are also associated with the incidence of leukopenia and thrombocytopenia, providing a scientific basis for formulating personalized treatment plans in clinical practice. In the future, with the continuous development of precision medicine, individualized chemotherapy strategies based on genetic typing are expected to further improve the treatment effect and quality of life of cancer patients.

In exploring the relationship between UGT1A16 and UGT1A128 polymorphisms and the efficacy of irinotecan (IRI), this study indeed encountered and identified several limitations that need to be addressed and improved in future research: (1) Publication Bias Due to Incomplete Literature Coverage: During the literature search process, this study may have overlooked some conference papers, gray literature (such as unpublished research reports, dissertations, etc.), and other relevant literature. These documents may contain important research data and conclusions. This incomplete coverage of literature may lead to publication bias, where certain types or results of studies are not included, affecting the representativeness of the overall conclusion. (2) Geographical Limitation and Publication Bias: All the original literature included in this study originated from China. This geographical limitation may question the universality and applicability of the research results. Domestic studies may be influenced by factors such as specific medical environments, patient population characteristics, and treatment options, making it difficult to generalize the research conclusions globally. Therefore, this geographical limitation may also lead to publication bias, as domestic research findings may not fully reflect the global situation. (3) Limitation in Genetic Model Analysis: Due to the constraints of the original literature data, this study only conducted an in-depth analysis of the recessive genetic model. However, the impact of genetic polymorphisms on drug response often involves complex interactions among multiple genetic models. Therefore, analyzing only the recessive genetic model may not fully reveal the complete relationship between UGT1A16 and UGT1A128 polymorphisms and the efficacy and adverse reactions of irinotecan. Future research should further expand to other genetic models to provide a more comprehensive assessment of genetic effects. (4) Lack of Analysis on Drug Dosage Effects: Drug dosage is one of the key factors affecting drug efficacy and adverse reactions. However, due to the limitations of the original literature data, this study did not conduct an in-depth analysis of adverse reactions caused by drug dosage. This limits our comprehensive understanding of the efficacy and safety of irinotecan at different doses. Future research should strengthen the exploration of drug dosage effects to guide individualized adjustments in clinical medication. (5) Challenge of Heterogeneity Among Studies: Differences in research methods, sample selection, data analysis, and other aspects among studies may lead to inconsistency or heterogeneity

	TAO/	0	TA0//+1	ATT		RISK RAUO	KISK RAUO
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.4.1 Grade 0-2							
HOU WJ 2023	8	32	15	45	8.1%	0.75 [0.36, 1.55]	
JI CS 2010	50	51	12	13	21.4%	1.06 [0.90, 1.25]	†
LU YL 2012	44	43	14	14		Not estimable	
WANG Q 2018	56	57	10	15	16.0%	1.47 [1.03, 2.11]	-
WU Q 2013	29	31	5	7	12.9%	1.31 [0.81, 2.11]	+
ZHAGN XJ 2012	46	47	6	9	13.2%	1.47 [0.92, 2.33]	
ZHANG CL 2019	27	28	10	10	21.6%	0.99 [0.85, 1.16]	t
Subtotal (95% CI)		289		113	93.2%	1.13 [0.96, 1.33]	•
Total events	260		72				
Heterogeneity: Tau ² :	= 0.02; Chi	² = 9.2	0, df = 5 (P	P = 0.10); I ² = 469	6	
Test for overall effect	:Z=1.43(P = 0.1	5)				
1.4.2 Grade 3-4 HOU WJ 2023	0	32	1	45	0.6%	0.46 [0.02, 11.05]	
JI CS 2010	1	51	1	13	0.9%	0.25 (0.02, 3.81)	
WANG Q 2018	1	57	5	15	1.4%	0.05 [0.01, 0.42]	
WU Q 2013	2	31	2	7	1.9%	0.23 [0.04, 1.34]	
ZHAGN XJ 2012	1	47	3	9	1.3%	0.06 (0.01, 0.55)	
ZHANG CL 2019	1	28	0	10	0.7%	1.14 [0.05, 25.89]	
Subtotal (95% CI)		246		99	6.8%	0.16 [0.06, 0.42]	•
Total events	6		12				
Heterogeneity: Tau ²	= 0.00; Chi	² = 4.0	2, df = 5 (F	P = 0.55); I ^z = 0%		
Test for overall effect	: Z = 3.74 ((P = 0.0	0002)				
Total (95% CI)		535		212	100.0%	1.01 [0.78, 1.31]	•
Total events	266		84				
Heterogeneity: Tau ²	= 0.07; Chi	² = 29.1	61, df = 11	(P = 0.	002); I ^z =	63%	
			10 14 19 19 19 19 19 19 19 19 19 19 19 19 19				0.003 0.1 1 10 200

FIGURE 12

Forest map of Meta-analysis results of the correlation between UGT1A1*28 gene polymorphism and the incidence of thrombocytopenia.



FIGURE 13

Forest map of Meta-analysis results of the correlation between UGT1A1*28 polymorphism and the incidence of hemoglobin.

Clinical efficacy and toxicity	DW vs. S	V	DW vs. I	DV	SV vs. DV		
	OR (95%Cl)	Р	OR (95%CI)	Р	OR (95%CI)	Р	
RR	1.65 [0.89, 3.05]	0.11	1.45 [0.55, 3.84]	0.45	0.56 [0.21, 1.50]	0.25	
Grade 0–2 diarrhea	0.60 [0.27, 1.37]	0.23	0.78 [0.16, 3.77]	0.76	1.58 [1.15, 2.18]	0.005	
Grade 3–4 diarrhea	0.48 [0.30, 0.78]	0.003	0.14 [0.07, 0.25]	< 0.00001	0.33 [0.19, 0.57]	< 0.0001	
Grade 0–2 neutropenia	0.93 [0.56, 1.54]	0.77	1.50 [1.03, 2.19]	0.03	1.81 [1.00, 3.29]	0.05	
Grade 3-4 neutropenia	1.13 [0.76, 1.69]	0.54	0.46 [0.31, 0.69]	0.0002	0.36 [0.23, 0.57]	<0.0001	
Grade 0–2 leukopenia	1.04 [0.76, 1.43]	0.81	1.95 [0.60, 6.37]	0.27	2.01 [0.60, 6.69]	0.26	
Grade 3–4 leukopenia	0.94 [0.45, 1.98]	0.88	1.09 [0.25, 4.72]	0.91	0.89 [0.21, 3.78]	0.88	

TABLE 2 Meta-analysis results of the clinical efficacy and toxicity of UGT1A1*6 and UGT1A1*28 gene polymorphism in IRI treatment of tumors.

Notes: RR, disease remission rate; DW, double wild type; SV, single variant; DV, double variant.



in research results. This heterogeneity increases the difficulty of interpreting the results and may weaken the reliability of the research conclusions. To overcome this challenge, future research should adopt uniform research designs and analytical methods as much as possible and strengthen international cooperation and exchange to form more consistent and reliable research conclusions.

In summary, although this study revealed a close relationship between UGT1A16 and UGT1A128 polymorphisms and irinotecan toxicity, it did not find a significant difference in short-term efficacy. This conclusion is limited by the number and quality of the studies included. To enhance the universality and reliability of the results, future research should consider incorporating more international data to expand the sample size and diversify research methods. At the same time, in-depth analysis of genetic models, drug dosage effects, and heterogeneity among studies should be strengthened to promote the in-depth development of research in this field.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

SG: Formal Analysis, Writing-original draft, Writing-review and editing. YS: Formal Analysis, Writing-original draft, Writing-review and editing. CZ: Formal Analysis, Methodology, Writing-original draft. NW: Data curation, Formal Analysis, Writing-original draft. XG: Data curation, Methodology, Writing-original draft. XL: Data curation, Software, Writing-original draft. NS: Formal Analysis, Methodology, Writing-review and editing.

Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

Bai, Y., Wu, H. W., Ma, X., Liu, Y., and Zhang, Y. H. (2017). Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy. *Onco Targets Ther.* 10, 3071–3081. doi:10.2147/OTT.S137644

Bailly, C. (2019). Irinotecan: 25 years of cancer treatment. *Pharmacol. Res.* 148, 104398. doi:10.1016/j.phrs.2019.104398

Chen, Ru., Su, Y., and Liu, J. (2017). Effect of UGT1A1 genotype polymorphism on the efficacy and adverse reactions of irinotecan in patients with advanced colorectal cancer. *China Cancer Clin. Rehabilitation* 24, 1040–1044.

Chen, S., Mo, Q., Xu, J., Shen, Y. Q., Lin, Z., Guo, C. X., et al. (2018). Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy response in Guangxi Zhuang patients with metastatic colorectal cancer. *Chin. J. Cancer Prev. Treat.* 25, 1335–1342.

Chen, X., Liu, L., Guo, Z., Liang, W., He, J., Huang, L., et al. (2017). UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis. *Cancer Chemother. Pharmacol.* 79, 1109–1117. doi:10.1007/s00280-017-3306-9

Dean, L. (2018). *Irinotecan therapy and UGT1A1 genotype*. Bethesda (MD): National Center for Biotechnology Information.

De Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., and Bins, S. (2018). Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. *Clin. Pharmacokinet.* 57, 1229–1254. doi:10.1007/s40262-018-0644-7

Deng, L. F. (2021). Comparison of the efficacy and safety of irinotecan + capecitabine or irinotecan + leucovorin regimen in combination with cetuximab in treating metastatic left colon cancer. *Chin. Res. Hosp.* 8, 47–50.

Etienne-Grimaldi, M. C., Boyer, J. C., Thomas, F., Quaranta, S., Picard, N., Loriot, M. A., et al. (2015). UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. *Fundam. Clin. Pharmacol.* 29, 219–237. doi:10. 1111/fcp.12117

Goon, C. P., Wang, L. Z., Wong, F. C., Thuya, W. L., Ho, P. C. L., and Goh, B. C. (2016). UGT1A1 mediated drug interactions and its clinical relevance. *Curr. Drug Metab.* 17, 100–106. doi:10.2174/1389200216666151103121253

Hirose, K., Kozu, C., Yamashita, K., Maruo, E., Kitamura, M., Hasegawa, J., et al. (2012). Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene. Oncol. Lett. 3, 694–698. doi:10.3892/ol.2011.533

Hou, W., Zhou, Q., Zhang, Y., Wang, J., Ding, H., and Zhang, L. (2023). Correlation analysis between UGT1A1 gene polymorphism and toxicity and survival of patients with small cell lung cancer treated with irinotecan. *J. Clin. Pulm.* 28, 1297–1320.

Hua, L., Chen, H., Chen, S., and Huang, H. (2019). The correlation between UGT1A1 * 28/6 gene polymorphism and irinotecan chemotherapy for advanced colorectal cancer in Guangxi Zhuang. *J. Oncol.* 25, 1042–1048.

Ji, C., Shu, H., Fu, H., Wang, G., Yao, Y., Chen, J., et al. (2010). Relationship between UGT1A1~* 28 gene polymorphism and chemotherapy efficacy and adverse reactions of irinotecan in advanced colorectal cancer. *Tumour* 30, 870–874.

Jia, X., and Fu, H. (2019). Oral mucosal swabs were used to detect UGT1A1 gene polymorphism and analyze its relationship with irinotecan adverse drug reactions. *Pract. Med. J.* 36, 393–397.

Kane, M., et al. (2023). "Atazanavir therapy and UGT1A1 genotype," in *Medical genetics summaries*. Editors V. M. Pratt, S. A. Scott, M. Pirmohamed, B. Esquivel, B. L. Kattman, and A. J. Malheiro (Bethesda (MD): National Center for Biotechnology Information).

Lazarus, G., Audrey, J., and Iskandar, A. W. B. (2019). Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic review. *Oncol. Rev.* 13, 425. doi:10.4081/oncol.2019.425

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Li, M., Wang, Z., Guo, J., Liu, J., Li, C., Liu, L., et al. (2014). Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer. *Onco Targets Ther.* 23, 1653–1661. doi:10.2147/OTT.S67867

Lv, y., Liu, W., Du, Y. J., Feng, Li., Wang, Y. D., Wang, L., et al. (2012). Clinical study on the relationship between UGT1A1 gene polymorphism and the safety and efficacy of irinotecan. *China Cancer Clin.* 39, 1542–1546.

Matsuoka, A., and Ando, Y. (2015). UGT1A1 genotyping for proper use of irinotecan. Rinsho Byori 63, 876–882.

Nelson, R. S., Seligson, N. D., Bottiglieri, S., Carballido, E., Cueto, A. D., Imanirad, I., et al. (2021). UGT1A1 guided cancer therapy: review of the evidence and considera -tions for clinical implementation. *Cancers (Basel)* 13, 1566. doi:10.3390/ cancers13071566

Pan, R., Wang, F., Gu, X. Y., Zhang, H., Deng, J. Z., Lu, W. B., et al. (2017). Polypeptide of UGT1A1 gene and clinical analysis of irinotecan combined with raltitrexed in the treatment of advanced colorectal cancer. *Chin. Foreign Med.* 36, 40–43.

Paulík, A., Nekvindová, J., and Filip, S. (2020). Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine. *Tumori* 106, 87–94. doi:10.1177/0300891618811283

Takano, M., and Sugiyama, T. (2017). UGT1A1 polymorphisms in cancer: impact on irinotecan treatment. *Pharmgenomics Pers. Med.* 10, 61–68. doi:10.2147/PGPM. S108656

Walter, N. A., McWeeney, S. K., Peters, S. T., Belknap, J. K., Hitzemann, R., and Buck, K. J. (2008). Single-nucleotide polymorphism masking. *Alcohol Res. Health* 31, 270–271.

Wang, Y., Ge, F. J., Lin, L., Hao, G. T., Shen, L., Xu, N., et al. (2012). Correlation analysis between UGT1A1 gene polymorphism and the toxicity and efficacy of irinotecan in the treatment of advanced colorectal cancer. J. Clin. Oncol. 17, 961–966.

Wang, Q., Ge, Q., and Li, L. L. (2018). Relationship between UGT1A1 gene polymorphism and the efficacy and safety of irinotecan in the treatment of colorectal cance. *Zhejiang J. Integr. Traditional Chin. West. Med.* 28, 193–197.

Wu, Q., Wang, R., Chen, Y. Q., Zhao, F. Y., Li, Y. M., Yang, Y., et al. (2013). Clinical significance of UGT1A1 gene polymorphism in secondline treatment of metastatic colorectal cancer with FOLFIRI regimen. *J. Clin. Oncol.* 18, 990–995.

Xu, C., Tang, X., Qu, Y., Keyoumu, S., Zhou, N., and Tang, Y. (2016). UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer. *Cancer Chemother. Pharmacol.* 78, 119–130. doi:10.1007/s00280-016-3057-z

Yang, M., Zhang, Y., Wang, X., Zhou, H., Zhang, N., and Wang, Y. (2017). The relationship between UGT1A1 gene polymorphism and the clinical safety and efficacy of irinotecan. *Mod. Oncol.* 25, 252–256.

Yin, H., and Gao, Y. (2014). Correlation between UGT1A1*28 and UGT1A1*6 gene polymorphisms and adverse reactions of irinotecan in China. *Jiangsu Med.* 40, 2307–2309.

Zhang, C., Li, M., Wang, J., Wang, S., and Fan, G. (2019). A study on the correlation between UGT1A1 gene polymorphism and adverse reactions of irinotecan hematological system in Han tumor patients in a tertiary hospita. *Chin. Pharm.* 22, 1076–1080.

Zhang, J., Wang, C., Huang, M., Fu, X., Lu, B., and Deng, Y. (2012). Relationship between UGT1A1 gene polymorphism and chemotherapy toxicity and efficacy of irinotecan for metastatic colorectal cancer. *China J. Pathophysiol.* 28, 823–828.

Zhang, Y., Su, D., Zhang, T., Mao, Z., and Bai, L. (2014). Relationship between UGT1A1 gene polymorphism and the toxicity and efficacy of irinotecan in the treatment of advanced colorectal cancer. *Chin. J. drug Appl. Monit.* 11, 263–266.

Zhou, C. F., Ma, T., Su, Y., Ye, Z. b., Ji, J., Yu, Y. y., et al. (2013). UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer. *Anticancer Agents Med. Chem.* 13, 235–241. doi:10.2174/1871520611313020008